How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of focal therapy using high-intensity focused ultrasound for localised prostate cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    Description of the procedure

    Indications and current treatment

    Prostate cancer causes the prostate to enlarge, resulting in symptoms such as difficulty in urinating and frequent urination. Localised prostate cancer is confined to the prostate and has not spread to nearby tissues or to other parts of the body.

    Decisions on treatment are based on imaging, tumour staging, risk assessment, and prostate-specific antigen (PSA) levels. For some people, localised prostate cancer grows slowly or not at all, and treatment may not be necessary. In such cases, watchful waiting or active surveillance strategies may be appropriate. If treatment is needed, several options are available. These include radical treatments (such as radical prostatectomy, external beam radiotherapy [EBRT], and radical brachytherapy), focal treatments (such as focal high-intensity focused ultrasound [HIFU], focal cryoablation, irreversible electroporation, focal laser ablation, and focal brachytherapy), and adjunctive treatments (such as chemotherapy and androgen deprivation therapy [ADT]).

    What the procedure involves

    Imaging and biopsy mapping are used to confirm that the tumour is suitable for focal therapy and to show its precise location. With the person under spinal or general anaesthesia, the bladder is catheterised using a urethral or supra-pubic catheter and the HIFU probe is inserted transrectally. Ultrasound imaging guidance is used to position the probe and to monitor the procedure. Pulses of HIFU are directed at the targeted part of the prostate, inducing tumour necrosis by a thermal effect, and causing cavitation (which can be visualised by ultrasound to assess the adequacy of treatment) until satisfactory ablation of the target area is judged to have occurred. This procedure differs from standard whole-gland HIFU in that only some of the prostate is treated. Transurethral resection of the prostate (TURP) may be done at the same time as focal HIFU to reduce urinary symptoms.

    After treatment, follow up consists of repeated PSA measurements and biopsies to detect recurrence.